Back to Trials
NCT06575075PHASE1, PHASE2Recruiting

Pilot Study of RR-HNK in OCD

Carolyn Rodriguez

Start Date

1/23/2026

Completion Date

11/30/2029

Summary

The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.

Detailed Description

This protocol examines the safety and efficacy of 2 dosage levels of intravenous RR-HNK administration in individuals with OCD.

Eligibility Criteria

Age Range: 18 years to 65 years

Inclusion Criteria: * Ages 18-65 * Meet the criteria for OCD diagnosis * Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI/CBT) or or had refused these treatments for individual reasons * Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures. * Able to provide informed consent Exclusion Criteria: * Allergy or hypersensitivity to ketamine * Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician * Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control * Lifetime history of deep brain stimulation

Interventions

DRUG

RR-HNK/Hydroxynorketamine

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Obsessive-Compulsive Disorder

Locations

Stanford University School of Medicine

Palo Alto, California 94305

United States